Form 4 for PCVX Vaxcyte, Inc.
Accepted 2022-03-04 00:00:00 ET · period of report 2022-03-02 · accession 0001209191-22-016524 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-04 | 2022-03-02 | PCVX | Fairman Jeff | VP, Research | A - Grant | $0.00 | +6,000 | 16.6K | +56% | $0 |
| D | 2022-03-04 | 2022-03-02 | PCVX | Fairman Jeff | VP, Research | A - Grant | $0.00 | +33.0K | 33.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-02 | A | A | 6,000 | $0.00 | 16,629 | D | — | — | (F1) Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter. |
| 2 | Derivative | Stock Option (right to buy) | 2022-03-02 | A | A | 33,000 | $0.00 | 33,000 | D | $24.79 · — to 2032-03-01 | 33,000 Common Stock | (F2) 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter. |